AMP010014A09 in Sus Scrofa Encodes an Analog of G Protein-Coupled Receptor 109A, Which Mediates the Anti-Inflammatory Effects of Beta-Hydroxybutyric Acid

Cellular Physiology and Biochemistry

Volumn 42, Issue 4, 2017, Pages 1420-1430

  Chen, Guangxin ^a   Fu, Shoupeng ^a   Feng, Wenqian ^a   Huang, Bingxu ^a   Xu, Shiyao ^a   Wang, Wei ^a   Liu, Juxiong ^a  

^a JILIN UNIVERSITY   (China)

Author keywords

AMP+; GPCRs; IPEC J2; Monocytes; ST; Swine

Indexed keywords

3 HYDROXYBUTYRIC ACID; CYCLIC AMP; CYCLOOXYGENASE 2; FORSKOLIN; G PROTEIN COUPLED RECEPTOR; G PROTEIN COUPLED RECEPTOR 109A; INTERLEUKIN 1BETA; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG; HCAR2 PROTEIN, HUMAN; HCAR2 PROTEIN, MOUSE; HCAR2 PROTEIN, RAT; ISOPROTEIN; NICOTINIC RECEPTOR; NONSTEROID ANTIINFLAMMATORY AGENT; SMALL INTERFERING RNA;

AMP010014A09 GENE; ANIMAL CELL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BIOACCUMULATION; CONTROLLED STUDY; CYTOKINE RELEASE; GENE; GENE SILENCING; GENETIC TRANSFECTION; MALE; MONOCYTE; NONHUMAN; PIG; PRIORITY JOURNAL; PROTEIN ANALYSIS; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; RNA INTERFERENCE; SEQUENCE HOMOLOGY; TESTICULAR CELL LINE; ANIMAL; ANTAGONISTS AND INHIBITORS; CELL LINE; CYTOLOGY; DRUG EFFECTS; EPITHELIUM CELL; GENE EXPRESSION; GENETICS; IMMUNOLOGY; INTESTINE; METABOLISM; MOUSE; PRIMARY CELL CULTURE; PROSTATE; RAT; SIGNAL TRANSDUCTION;

3-HYDROXYBUTYRIC ACID; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CELL LINE; COLFORSIN; CYCLIC AMP; EPITHELIAL CELLS; GENE EXPRESSION; INTESTINES; LIPOPOLYSACCHARIDES; MALE; MICE; MONOCYTES; PRIMARY CELL CULTURE; PROSTATE; PROTEIN ISOFORMS; RATS; RECEPTORS, G-PROTEIN-COUPLED; RECEPTORS, NICOTINIC; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; SWINE;

EID: 85025453381     PISSN: 10158987     EISSN: 14219778     Source Type: Journal    
DOI: 10.1159/000479206     Document Type: Article

References (49)

1. Lee DK, Nguyen T, Lynch KR, Cheng R, Vanti WB, Arkhitko O, Lewis T, Evans JF, George SR, O'Dowd BF: Discovery and mapping of ten novel G protein-coupled receptor genes. Gene 2001;275:83-91.
2. Nomura H, Nielsen BW, Matsushima K: Molecular cloning of cDNAs encoding a LD78 receptor and putative leukocyte chemotactic peptide receptors. Int Immunol 1993;5:1239-1249.
3. Ahmed K, Tunaru S, Langhans CD, Hanson J, Michalski CW, Kolker S, Jones PM, Okun JG, Offermanns S: Deorphanization of GPR109B as a receptor for the beta-oxidation intermediate 3-OH-octanoic acid and its role in the regulation of lipolysis. J Biol Chem 2009;284:21928-21933.
4. Soga T, Kamohara M, Takasaki J, Matsumoto S, Saito T, Ohishi T, Hiyama H, Matsuo A, Matsushime H, Furuichi K: Molecular identification of nicotinic acid receptor. Biochem Biophys Res Commun 2003;303:364-369.
5. Tunaru S, Kero J, Schaub A, Wufka C, Blaukat A, Pfeffer K, Offermanns S: PUMA-G and HM74 are receptors for nicotinic acid and mediate its anti-lipolytic effect. Nat Med 2003;9:352-355.
6. Wise A, Foord SM, Fraser NJ, Barnes AA, Elshourbagy N, Eilert M, Ignar DM, Murdock PR, Steplewski K, Green A, Brown AJ, Dowell SJ, Szekeres PG, Hassall DG, Marshall FH, Wilson S, Pike NB: Molecular identification of high and low affinity receptors for nicotinic acid. J Biol Chem 2003;278:9869-9874.
7. Taggart AK, Kero J, Gan X, Cai TQ, Cheng K, Ippolito M, Ren N, Kaplan R, Wu K, Wu TJ, Jin L, Liaw C, Chen R, Richman J, Connolly D, Offermanns S, Wright SD, Waters MG: (D)-beta-Hydroxybutyrate inhibits adipocyte lipolysis via the nicotinic acid receptor PUMA-G. J Biol Chem 2005;280:26649-26652.
8. Liu C, Wu J, Zhu J, Kuei C, Yu J, Shelton J, Sutton SW, Li X, Yun SJ, Mirzadegan T, Mazur C, Kamme F, Lovenberg TW: Lactate inhibits lipolysis in fat cells through activation of an orphan G-protein-coupled receptor, GPR81. J Biol Chem 2009;284:2811-2822.
9. Cai TQ, Ren N, Jin L, Cheng K, Kash S, Chen R, Wright SD, Taggart AK, Waters MG: Role of GPR81 in lactate-mediated reduction of adipose lipolysis. Biochem Biophys Res Commun 2008;377:987-991.
10. Torhan AS, Cheewatrakoolpong B, Kwee L, Greenfeder S: Cloning and characterization of the hamster and guinea pig nicotinic acid receptors. J Lipid Res 2007;48:2065-2071.
11. Shi X, Li X, Li D, Li Y, Song Y, Deng Q, Wang J, Zhang Y, Ding H, Yin L, Zhang Y, Wang Z, Li X, Liu G: beta-Hydroxybutyrate activates the NF-kappaB signaling pathway to promote the expression of pro-inflammatory factors in calf hepatocytes. Cell Physiol Biochem 2014;33:920-932.
12. Hanson J, Gille A, Zwykiel S, Lukasova M, Clausen BE, Ahmed K, Tunaru S, Wirth A, Offermanns S: Nicotinic acid-and monomethyl fumarate-induced flushing involves GPR109A expressed by keratinocytes and COX-2-dependent prostanoid formation in mice. J Clin Invest 2010;120:2910-2919.
13. Maciejewski-Lenoir D, Richman JG, Hakak Y, Gaidarov I, Behan DP, Connolly DT: Langerhans cells release prostaglandin D2 in response to nicotinic acid. J Invest Dermatol 2006;126:2637-2646.
14. Tang H, Lu JY, Zheng X, Yang Y, Reagan JD: The psoriasis drug monomethylfumarate is a potent nicotinic acid receptor agonist. Biochem Biophys Res Commun 2008;375:562-565.
15. Schaub A, Futterer A, Pfeffer K: PUMA-G, an IFN-gamma-inducible gene in macrophages is a novel member of the seven transmembrane spanning receptor superfamily. Eur J Immunol 2001;31:3714-3725.
16. Hughes-Large JM, Pang DK, Robson DL, Chan P, Toma J, Borradaile NM: Niacin receptor activation improves Human microvascular endothelial cell angiogenic function during lipotoxicity. Atherosclerosis 2014;237:696-704.
17. Elangovan S, Pathania R, Ramachandran S, Ananth S, Padia RN, Lan L, Singh N, Martin PM, Hawthorn L, Prasad PD, Ganapathy V, Thangaraju M: The niacin/butyrate receptor GPR109A suppresses mammary tumorigenesis by inhibiting cell survival. Cancer Res 2014;74:1166-1178.
18. Gambhir D, Ananth S, Veeranan-Karmegam R, Elangovan S, Hester S, Jennings E, Offermanns S, Nussbaum JJ, Smith SB, Thangaraju M, Ganapathy V, Martin PM: GPR109A as an anti-inflammatory receptor in retinal pigment epithelial cells and its relevance to diabetic retinopathy. Invest Ophthalmol Vis Sci 2012;53:2208-2217.
19. Kostylina G, Simon D, Fey MF, Yousefi S, Simon HU: Neutrophil apoptosis mediated by nicotinic acid receptors (GPR109A). Cell Death Differ 2008;15:134-142.
20. Rahman M, Muhammad S, Khan MA, Chen H, Ridder DA, Muller-Fielitz H, Pokorna B, Vollbrandt T, Stolting I, Nadrowitz R, Okun JG, Offermanns S, Schwaninger M: The beta-hydroxybutyrate receptor HCA2 activates a neuroprotective subset of macrophages. Nat Commun 2014;5:3944.
21. Carlson LA, Oro L: The effect of nicotinic acid on the plasma free fatty acid; demonstration of a metabolic type of sympathicolysis. Acta Med Scand 1962;172:641-645.
22. Carlson LA: Studies on the effect of nicotinic acid on catecholamine stimulated lipolysis in adipose tissue in vitro. Acta Med Scand 1963;173:719-722.
23. Guilloteau P, Martin L, Eeckhaut V, Ducatelle R, Zabielski R, Van Immerseel F: From the gut to the peripheral tissues: the multiple effects of butyrate. Nutr Res Rev 2010;23:366-384.
24. Leonel AJ, Alvarez-Leite JI: Butyrate: implications for intestinal function. Curr Opin Clin Nutr Metab Care 2012;15:474-479.
25. Macfarlane S, Macfarlane GT: Regulation of short-chain fatty acid production. Proc Nutr Soc 2003;62:67-72.
26. Chen J, Li Y, Tian Y, Huang C, Li D, Zhong Q, Ma X: Interaction between Microbes and Host Intestinal Health: Modulation by Dietary Nutrients and Gut-Brain-Endocrine-Immune Axis. Curr Protein Pept Sci 2015;16:592-603.
27. Wang HB, Wang PY, Wang X, Wan YL, Liu YC: Butyrate enhances intestinal epithelial barrier function via up-regulation of tight junction protein Claudin-1 transcription. Dig Dis Sci 2012;57:3126-3135.
28. Peng L, Li ZR, Green RS, Holzman IR, Lin J: Butyrate enhances the intestinal barrier by facilitating tight junction assembly via activation of AMP-activated protein kinase in Caco-2 cell monolayers. J Nutr 2009;139:1619-1625.
29. Peng L, He Z, Chen W, Holzman IR, Lin J: Effects of butyrate on intestinal barrier function in a Caco-2 cell monolayer model of intestinal barrier. Pediatr Res 2007;61:37-41.
30. Fang CL, Sun H, Wu J, Niu HH, Feng J: Effects of sodium butyrate on growth performance, haematological and immunological characteristics of weanling piglets. J Anim Physiol Anim Nutr (Berl) 2014;98:680-685.
31. Huang C, Song P, Fan P, Hou C, Thacker P, Ma X: Dietary Sodium Butyrate Decreases Postweaning Diarrhea by Modulating Intestinal Permeability and Changing the Bacterial Communities in Weaned Piglets. J Nutr 2015;145:2774-2780.
32. Uenishi H, Eguchi T, Suzuki K, Sawazaki T, Toki D, Shinkai H, Okumura N, Hamasima N, Awata T: PEDE (Pig EST Data Explorer): construction of a database for ESTs derived from porcine full-length cDNA libraries. Nucleic Acids Res 2004;32:D484-488.
33. Sun L, Zhao M, Zhang J, Lv M, Li Y, Yang X, Liu A, Wu Z: MiR-29b Downregulation Induces Phenotypic Modulation of Vascular Smooth Muscle Cells: Implication for Intracranial Aneurysm Formation and Progression to Rupture. Cell Physiol Biochem 2017;41:510-518.
34. Halmer R, Davies L, Liu Y, Fassbender K, Walter S: The Innate Immune Receptor CD14 Mediates Lymphocyte Migration in EAE. Cell Physiol Biochem 2015;37:269-275.
35. Song L, Kang C, Sun Y, Huang W, Liu W, Qian Z: Crocetin Inhibits Lipopolysaccharide-Induced Inflammatory Response in Human Umbilical Vein Endothelial Cells. Cell Physiol Biochem 2016;40:443-452.
36. Fu SP, Li SN, Wang JF, Li Y, Xie SS, Xue WJ, Liu HM, Huang BX, Lv QK, Lei LC, Liu GW, Wang W, Liu JX: BHBA suppresses LPS-induced inflammation in BV-2 cells by inhibiting NF-kappaB activation. Mediators Inflamm 2014;2014:983401.
37. Fu SP, Wang JF, Xue WJ, Liu HM, Liu BR, Zeng YL, Li SN, Huang BX, Lv QK, Wang W, Liu JX: Anti-inflammatory effects of BHBA in both in vivo and in vitro Parkinson's disease models are mediated by GPR109A-dependent mechanisms. J Neuroinflammation 2015;12:9.
38. Digby JE, Martinez F, Jefferson A, Ruparelia N, Chai J, Wamil M, Greaves DR, Choudhury RP: Anti-inflammatory effects of nicotinic acid in Human monocytes are mediated by GPR109A dependent mechanisms. Arterioscler Thromb Vasc Biol 2012;32:669-676.
39. Digby JE, McNeill E, Dyar OJ, Lam V, Greaves DR, Choudhury RP: Anti-inflammatory effects of nicotinic acid in adipocytes demonstrated by suppression of fractalkine, RANTES, and MCP-1 and upregulation of adiponectin. Atherosclerosis 2010;209:89-95.
40. Chai JT, Digby JE, Ruparelia N, Jefferson A, Handa A, Choudhury RP: Nicotinic acid receptor GPR109A is down-regulated in Human macrophage-derived foam cells. PLoS One 2013;8:e62934.
41. Li G, Shi Y, Huang H, Zhang Y, Wu K, Luo J, Sun Y, Lu J, Benovic JL, Zhou N: Internalization of the Human nicotinic acid receptor GPR109A is regulated by G(i), GRK2, and arrestin3. J Biol Chem 2010;285:22605-22618.
42. Walters RW, Shukla AK, Kovacs JJ, Violin JD, DeWire SM, Lam CM, Chen JR, Muehlbauer MJ, Whalen EJ, Lefkowitz RJ: beta-Arrestin1 mediates nicotinic acid-induced flushing, but not its antilipolytic effect, in mice. J Clin Invest 2009;119:1312-1321.
43. Li X, Millar JS, Brownell N, Briand F, Rader DJ: Modulation of HDL metabolism by the niacin receptor GPR109A in mouse hepatocytes. Biochem Pharmacol 2010;80:1450-1457.
44. Lukasova M, Malaval C, Gille A, Kero J, Offermanns S: Nicotinic acid inhibits progression of atherosclerosis in mice through its receptor GPR109A expressed by immune cells. J Clin Invest 2011;121:1163-1173.
45. Kwon WY, Suh GJ, Kim KS, Kwak YH: Niacin attenuates lung inflammation and improves survival during sepsis by downregulating the nuclear factor-kappaB pathway. Crit Care Med 2011;39:328-334.
46. Wanders D, Graff EC, White BD, Judd RL: Niacin increases adiponectin and decreases adipose tissue inflammation in high fat diet-fed mice. PLoS One 2013;8:e71285.
47. Cho KH, Kim HJ, Rodriguez-Iturbe B, Vaziri ND: Niacin ameliorates oxidative stress, inflammation, proteinuria, and hypertension in rats with chronic renal failure. Am J Physiol Renal Physiol 2009;297:F106-113.
48. Carlson LA: Nicotinic acid: the broad-spectrum lipid drug. A 50th anniversary review. J Intern Med 2005;258:94-114.
49. Meyers CD, Kamanna VS, Kashyap ML: Niacin therapy in atherosclerosis. Curr Opin Lipidol 2004;15:659-665.